Skip to content

EBITDA at other companies

AMP
Amphastar PharmaceuticalsAMPH
$27.98M-45.0%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$86.83M+11.0%
Opko Health logo
Opko HealthOPK
-$28.82M+34.0%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Calculated from Emergent Biosolutions’s reported figures.

$10.5Mebit+
$23.5MDepreciation Depletion & Amortization
=$34M

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's EBITDA?
Emergent Biosolutions (EBS) reported EBITDA of $34M in Q1 2026.
How has Emergent Biosolutions's EBITDA changed year-over-year?
Emergent Biosolutions's EBITDA decreased by 54.8% year-over-year, from $75.3M to $34M.
What is the long-term trend for Emergent Biosolutions's EBITDA?
Over 3 years (2021 to 2024), Emergent Biosolutions's EBITDA has grown at a -94.0% compound annual growth rate (CAGR), from $465.2M to $100K.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.